Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2012

Open Access 01-12-2012 | Research

MSH2 and CXCR4 involvement in malignant VIPoma

Authors: Sven Müller, Susan Kupka, Ingmar Königsrainer, Hinnak Northoff, Karl Sotlar, Thomas Bock, Reinhard Kandolf, Frank Traub, Alfred Königsrainer, Derek Zieker

Published in: World Journal of Surgical Oncology | Issue 1/2012

Login to get access

Abstract

Background

Vasoactive intestinal polypeptide secreting tumors(VIPomas) are rare endocrine tumors of the pancreas with an estimated incidence of 0.1 per million per year. The molecular mechanisms that mediate development of VIPomas are poorly investigated and require definition.

Methods

A genome- and gene expression analysis of specimens of a primary pancreatic VIPoma with hepatic metastases was performed. The primary tumor, the metastases, the corresponding healthy tissue of the liver, and the pancreas were compared with each other using oligonucleotide microarrays and loss of heterozygosity (LOH).

Results

The results revealed multiple LOH events and several differentially expressed genes. Our finding of LOH and downregulation was conspicuous in the microarray analysis for the mismatch repair gene MSH2 in the primary pancreatic VIPoma tumor, the hepatic metastasis but not in the corresponding healthy tissue. Further a strong overexpression of the chemokine CXCR4 was detected in the hepatic metastases compared to its pancreatic primary. With a review of the literature we describe the molecular insights of metastatic development in VIPoma.

Conclusion

In VIPoma, defects in the mismatch repair system especially in MSH2 may contribute to carcinogenesis, and increased CXCR4 may be associated with liver metastasis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Verner JV, Morrison AB: Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med. 1958, 25: 374-380. 10.1016/0002-9343(58)90075-5.CrossRefPubMed Verner JV, Morrison AB: Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med. 1958, 25: 374-380. 10.1016/0002-9343(58)90075-5.CrossRefPubMed
2.
go back to reference Friesen SR: Update on the diagnosis and treatment of rare neuroendocrine tumors. Surg Clin North Am. 1987, 67: 379-393.PubMed Friesen SR: Update on the diagnosis and treatment of rare neuroendocrine tumors. Surg Clin North Am. 1987, 67: 379-393.PubMed
3.
go back to reference Ectors N: Pancreatic endocrine tumors: diagnostic pitfalls. Hepatogastroenterology. 1999, 46: 679-690.PubMed Ectors N: Pancreatic endocrine tumors: diagnostic pitfalls. Hepatogastroenterology. 1999, 46: 679-690.PubMed
4.
go back to reference Ghaferi AA, Chojnacki KA, Long WD, Cameron JL, Yeo CJ: Pancreatic VIPomas: subject review and one institutional experience. J Gastrointest Surg. 2008, 12: 382-393. 10.1007/s11605-007-0177-0.CrossRefPubMed Ghaferi AA, Chojnacki KA, Long WD, Cameron JL, Yeo CJ: Pancreatic VIPomas: subject review and one institutional experience. J Gastrointest Surg. 2008, 12: 382-393. 10.1007/s11605-007-0177-0.CrossRefPubMed
5.
go back to reference Peng SY, Li JT, Liu YB, Fang HQ, Wu YL, Peng CH, Wang XB, Qian HR: Diagnosis and treatment of VIPoma in China: (case report and 31 cases review) diagnosis and treatment of VIPoma. Pancreas. 2004, 28: 93-97. 10.1097/00006676-200401000-00015.CrossRefPubMed Peng SY, Li JT, Liu YB, Fang HQ, Wu YL, Peng CH, Wang XB, Qian HR: Diagnosis and treatment of VIPoma in China: (case report and 31 cases review) diagnosis and treatment of VIPoma. Pancreas. 2004, 28: 93-97. 10.1097/00006676-200401000-00015.CrossRefPubMed
6.
go back to reference Grant CS: Surgical management of malignant islet cell tumors. World J Surg. 1993, 17: 498-503. 10.1007/BF01655109.CrossRefPubMed Grant CS: Surgical management of malignant islet cell tumors. World J Surg. 1993, 17: 498-503. 10.1007/BF01655109.CrossRefPubMed
7.
go back to reference Zieker D, Zieker J, Dietzsch J, Burnet M, Northoff H, Fehrenbach E: CDNA-microarray analysis as a research tool for expression profiling in human peripheral blood following exercise. Exerc Immunol Rev. 2005, 11: 1186-1196. Zieker D, Zieker J, Dietzsch J, Burnet M, Northoff H, Fehrenbach E: CDNA-microarray analysis as a research tool for expression profiling in human peripheral blood following exercise. Exerc Immunol Rev. 2005, 11: 1186-1196.
8.
go back to reference Zieker D, Fehrenbach E, Dietzsch J, Fliegner J, Waidmann M, Nieselt K, Gebicke-Haerter P, Spanagel R, Simon P, Niess AM, Northoff H: cDNA microarray analysis reveals novel candidate genes expressed in human peripheral blood following exhaustive exercise. Physiol Genomics. 2005, 23: 287-294. 10.1152/physiolgenomics.00096.2005.CrossRefPubMed Zieker D, Fehrenbach E, Dietzsch J, Fliegner J, Waidmann M, Nieselt K, Gebicke-Haerter P, Spanagel R, Simon P, Niess AM, Northoff H: cDNA microarray analysis reveals novel candidate genes expressed in human peripheral blood following exhaustive exercise. Physiol Genomics. 2005, 23: 287-294. 10.1152/physiolgenomics.00096.2005.CrossRefPubMed
9.
go back to reference Kupka S, Haack B, Zdichavsky M, Mlinar T, Kienzle C, Bock T, Kandolf R, Kroeber SM, Konigsrainer A: Large proportion of low frequency microsatellite-instability and loss of heterozygosity in pheochromocytoma and endocrine tumors detected with an extended marker panel. J Cancer Res Clin Oncol. 2008, 134: 463-471. 10.1007/s00432-007-0307-9.CrossRefPubMed Kupka S, Haack B, Zdichavsky M, Mlinar T, Kienzle C, Bock T, Kandolf R, Kroeber SM, Konigsrainer A: Large proportion of low frequency microsatellite-instability and loss of heterozygosity in pheochromocytoma and endocrine tumors detected with an extended marker panel. J Cancer Res Clin Oncol. 2008, 134: 463-471. 10.1007/s00432-007-0307-9.CrossRefPubMed
10.
go back to reference Karnik P, Paris M, Williams BR, Casey G, Crowe J, Chen P: Two distinct tumor suppressor loci within chromosome 11p15 implicated in breast cancer progression and metastasis. Hum Mol Genet. 1998, 7: 895-903. 10.1093/hmg/7.5.895.CrossRefPubMed Karnik P, Paris M, Williams BR, Casey G, Crowe J, Chen P: Two distinct tumor suppressor loci within chromosome 11p15 implicated in breast cancer progression and metastasis. Hum Mol Genet. 1998, 7: 895-903. 10.1093/hmg/7.5.895.CrossRefPubMed
11.
go back to reference Capella C, Polak JM, Buffa R, Tapia FJ, Heitz P, Usellini L, Bloom SR, Solcia E: Morphologic patterns and diagnostic criteria of VIP-producing endocrine tumors. A histologic, histochemical, ultrastructural, and biochemical study of 32 cases. Cancer. 1983, 52: 1860-1874. 10.1002/1097-0142(19831115)52:10<1860::AID-CNCR2820521017>3.0.CO;2-F.CrossRefPubMed Capella C, Polak JM, Buffa R, Tapia FJ, Heitz P, Usellini L, Bloom SR, Solcia E: Morphologic patterns and diagnostic criteria of VIP-producing endocrine tumors. A histologic, histochemical, ultrastructural, and biochemical study of 32 cases. Cancer. 1983, 52: 1860-1874. 10.1002/1097-0142(19831115)52:10<1860::AID-CNCR2820521017>3.0.CO;2-F.CrossRefPubMed
12.
go back to reference Jensen RT: Pancreatic endocrine tumors: recent advances. Ann Oncol. 1999, Suppl: 4170-4176. Jensen RT: Pancreatic endocrine tumors: recent advances. Ann Oncol. 1999, Suppl: 4170-4176.
13.
go back to reference Barghorn A, Komminoth P, Bachmann D, Rutimann K, Saremaslani P, Muletta-Feurer S, Perren A, Roth J, Heitz PU, Speel EJ: Deletion at 3p25.3–p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression. J Pathol. 2001, 194: 451-458. 10.1002/path.886.CrossRefPubMed Barghorn A, Komminoth P, Bachmann D, Rutimann K, Saremaslani P, Muletta-Feurer S, Perren A, Roth J, Heitz PU, Speel EJ: Deletion at 3p25.3–p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression. J Pathol. 2001, 194: 451-458. 10.1002/path.886.CrossRefPubMed
14.
go back to reference Barghorn A, Speel EJ, Farspour B, Saremaslani P, Schmid S, Perren A, Roth J, Heitz PU, Komminoth P: Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors. Am J Pathol. 2001, 158: 1903-1911. 10.1016/S0002-9440(10)64658-5.PubMedCentralCrossRefPubMed Barghorn A, Speel EJ, Farspour B, Saremaslani P, Schmid S, Perren A, Roth J, Heitz PU, Komminoth P: Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors. Am J Pathol. 2001, 158: 1903-1911. 10.1016/S0002-9440(10)64658-5.PubMedCentralCrossRefPubMed
15.
go back to reference Bartsch D, Hahn SA, Danichevski KD, Ramaswamy A, Bastian D, Galehdari H, Barth P, Schmiegel W, Simon B, Rothmund M: Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. Oncogene. 1999, 18: 2367-2371. 10.1038/sj.onc.1202585.CrossRefPubMed Bartsch D, Hahn SA, Danichevski KD, Ramaswamy A, Bastian D, Galehdari H, Barth P, Schmiegel W, Simon B, Rothmund M: Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. Oncogene. 1999, 18: 2367-2371. 10.1038/sj.onc.1202585.CrossRefPubMed
16.
go back to reference Missiaglia E, Moore PS, Williamson J, Lemoine NR, Falconi M, Zamboni G, Scarpa A: Sex chromosome anomalies in pancreatic endocrine tumors. Int J Cancer. 2002, 98: 532-538. 10.1002/ijc.10223.CrossRefPubMed Missiaglia E, Moore PS, Williamson J, Lemoine NR, Falconi M, Zamboni G, Scarpa A: Sex chromosome anomalies in pancreatic endocrine tumors. Int J Cancer. 2002, 98: 532-538. 10.1002/ijc.10223.CrossRefPubMed
17.
go back to reference Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G, Pederzoli P, Croce CM, Scarpa A: Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol. 2010, 28: 245-255. 10.1200/JCO.2008.21.5988.PubMedCentralCrossRefPubMed Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G, Pederzoli P, Croce CM, Scarpa A: Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol. 2010, 28: 245-255. 10.1200/JCO.2008.21.5988.PubMedCentralCrossRefPubMed
18.
go back to reference Tannapfel A, Vomschloss S, Karhoff D, Markwarth A, Hengge UR, Wittekind C, Arnold R, Horsch D: BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors. Am J Clin Pathol. 2005, 123: 256-260. 10.1309/YQBR9C05RU4DD3RN.CrossRefPubMed Tannapfel A, Vomschloss S, Karhoff D, Markwarth A, Hengge UR, Wittekind C, Arnold R, Horsch D: BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors. Am J Clin Pathol. 2005, 123: 256-260. 10.1309/YQBR9C05RU4DD3RN.CrossRefPubMed
19.
go back to reference Arnason T, Sapp HL, Rayson D, Barnes PJ, Drewniak M, Nassar BA, Huang WY: Loss of expression of DNA mismatch repair proteins is rare in pancreatic and small intestinal neuroendocrine tumors. Arch Pathol Lab Med. 2011, 135: 1539-1544. 10.5858/arpa.2010-0560-OA.CrossRefPubMed Arnason T, Sapp HL, Rayson D, Barnes PJ, Drewniak M, Nassar BA, Huang WY: Loss of expression of DNA mismatch repair proteins is rare in pancreatic and small intestinal neuroendocrine tumors. Arch Pathol Lab Med. 2011, 135: 1539-1544. 10.5858/arpa.2010-0560-OA.CrossRefPubMed
20.
go back to reference O’Brien V, Brown R: Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis. 2006, 27: 682-692.CrossRefPubMed O’Brien V, Brown R: Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis. 2006, 27: 682-692.CrossRefPubMed
21.
go back to reference Peltomaki P: Deficient DNA, mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet. 2001, 10: 735-740. 10.1093/hmg/10.7.735.CrossRefPubMed Peltomaki P: Deficient DNA, mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet. 2001, 10: 735-740. 10.1093/hmg/10.7.735.CrossRefPubMed
22.
go back to reference Fishel R: Mismatch repair, molecular switches, and signal transduction. Genes Dev. 1998, 12: 2096-2101. 10.1101/gad.12.14.2096.CrossRefPubMed Fishel R: Mismatch repair, molecular switches, and signal transduction. Genes Dev. 1998, 12: 2096-2101. 10.1101/gad.12.14.2096.CrossRefPubMed
23.
go back to reference Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, Foshaq L, Bilchik AJ, Hoon DS: Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 2005, 23: 2744-2753.CrossRefPubMed Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, Foshaq L, Bilchik AJ, Hoon DS: Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 2005, 23: 2744-2753.CrossRefPubMed
24.
go back to reference Kim J, Mori T, Chen SL, Amersi FF, Martinez SR, Kuo C, Turner RR, Ye X, Bilchik AJ, Morton DL, Hoon DS: Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg. 2006, 244: 113-120. 10.1097/01.sla.0000217690.65909.9c.PubMedCentralCrossRefPubMed Kim J, Mori T, Chen SL, Amersi FF, Martinez SR, Kuo C, Turner RR, Ye X, Bilchik AJ, Morton DL, Hoon DS: Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg. 2006, 244: 113-120. 10.1097/01.sla.0000217690.65909.9c.PubMedCentralCrossRefPubMed
25.
26.
go back to reference Bottazzi B, Polentarutti N, Acero R, Balsari A, Boraschi D, Ghezzi P, Salmona M, Mantovani A: Regulation of the macrophage content of neoplasms by chemoattractants. Science. 1983, 220: 210-212. 10.1126/science.6828888.CrossRefPubMed Bottazzi B, Polentarutti N, Acero R, Balsari A, Boraschi D, Ghezzi P, Salmona M, Mantovani A: Regulation of the macrophage content of neoplasms by chemoattractants. Science. 1983, 220: 210-212. 10.1126/science.6828888.CrossRefPubMed
27.
go back to reference Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastequi E, Zlotnik A: Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001, 410: 50-56. 10.1038/35065016.CrossRefPubMed Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastequi E, Zlotnik A: Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001, 410: 50-56. 10.1038/35065016.CrossRefPubMed
28.
go back to reference Oonakahara K, Matsuyama W, Higashimoto I, Kawabata M, Arimura K, Osame M: Stromal-derived factor-1alpha/CXCL12-CXCR 4 axis is involved in the dissemination of NSCLC cells into pleural space. Am J Respir Cell Mol Biol. 2004, 30: 671-677. 10.1165/rcmb.2003-0340OC.CrossRefPubMed Oonakahara K, Matsuyama W, Higashimoto I, Kawabata M, Arimura K, Osame M: Stromal-derived factor-1alpha/CXCL12-CXCR 4 axis is involved in the dissemination of NSCLC cells into pleural space. Am J Respir Cell Mol Biol. 2004, 30: 671-677. 10.1165/rcmb.2003-0340OC.CrossRefPubMed
29.
go back to reference Saur D, Seidler B, Schneider G, Algul H, Beck R, Senekowitsch-Schmidtke R, Schwaiger M, Schmid RM: CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. Gastroenterology. 2005, 129: 1237-1250. 10.1053/j.gastro.2005.06.056.CrossRefPubMed Saur D, Seidler B, Schneider G, Algul H, Beck R, Senekowitsch-Schmidtke R, Schwaiger M, Schmid RM: CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. Gastroenterology. 2005, 129: 1237-1250. 10.1053/j.gastro.2005.06.056.CrossRefPubMed
30.
go back to reference Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK: Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002, 62: 1832-1837.PubMed Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK: Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002, 62: 1832-1837.PubMed
31.
go back to reference Wang J, Wang J, Dai J, Jung Y, Wei CL, Wang Y, Havens AM, Hogg PJ, Keller ET, Pienta KJ, Nor JE, Wang CY, Taichman RS: A glycolytic mechanism regulating an angiogenic switch in prostate cancer. Cancer Res. 2007, 67: 149-159. 10.1158/0008-5472.CAN-06-2971.CrossRefPubMed Wang J, Wang J, Dai J, Jung Y, Wei CL, Wang Y, Havens AM, Hogg PJ, Keller ET, Pienta KJ, Nor JE, Wang CY, Taichman RS: A glycolytic mechanism regulating an angiogenic switch in prostate cancer. Cancer Res. 2007, 67: 149-159. 10.1158/0008-5472.CAN-06-2971.CrossRefPubMed
32.
go back to reference Yasumoto K, Koizumi K, Kawashima A, Saitoh Y, Arita Y, Shinohara K, Minami T, Nakayama T, Sakurai H, Takahashi Y, Yoshie O, Saiki I: Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res. 2006, 66: 2181-2187. 10.1158/0008-5472.CAN-05-3393.CrossRefPubMed Yasumoto K, Koizumi K, Kawashima A, Saitoh Y, Arita Y, Shinohara K, Minami T, Nakayama T, Sakurai H, Takahashi Y, Yoshie O, Saiki I: Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res. 2006, 66: 2181-2187. 10.1158/0008-5472.CAN-05-3393.CrossRefPubMed
33.
go back to reference Deschamps L, Bacha D, Rebours V, Mebarki M, Bretagnol F, Panis Y, Bedossa P, Ruszniewski P, Coulevard A: The expression of the hypoxia markers CA9 and CXCR4 is correlated with survival in patients with neuroendocrine tumours of the ileum. Neuroendocrinology. 2012, 95: 214-222. 10.1159/000329873.CrossRefPubMed Deschamps L, Bacha D, Rebours V, Mebarki M, Bretagnol F, Panis Y, Bedossa P, Ruszniewski P, Coulevard A: The expression of the hypoxia markers CA9 and CXCR4 is correlated with survival in patients with neuroendocrine tumours of the ileum. Neuroendocrinology. 2012, 95: 214-222. 10.1159/000329873.CrossRefPubMed
Metadata
Title
MSH2 and CXCR4 involvement in malignant VIPoma
Authors
Sven Müller
Susan Kupka
Ingmar Königsrainer
Hinnak Northoff
Karl Sotlar
Thomas Bock
Reinhard Kandolf
Frank Traub
Alfred Königsrainer
Derek Zieker
Publication date
01-12-2012
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2012
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-10-264

Other articles of this Issue 1/2012

World Journal of Surgical Oncology 1/2012 Go to the issue